| Indicators | Browse All

Sensei Biotherapeutics Inc (SNSE)

Healthcare | Biotechnology | Rockville, United States |
USD

Short-term:★★★★⯪Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 9:54 a.m. UTC

The immediate catalyst is undeniable: the acquisition of Faeth Therapeutics and the subsequent rebranding have ignited a massive short-term rally, pushing shares from a low of $6.32 to a recent high of $25.00 within weeks. This momentum is further amplified by a 'strong buy' analyst consensus and a target price significantly higher than current levels, suggesting the market is pricing in a successful pivot to the PIKTOR therapy. However, this optimism is built entirely on a speculative foundation; the company has endured four consecutive years of double-digit declines, erasing nearly 95% of its value over the past four years, while burning through cash at an alarming rate with negative free cash flow exceeding $92 million. The balance sheet is precarious, showing negative book value and massive debt relative to assets, making it a classic high-risk biotech gamble rather than a sound investment. While the recent price action offers a compelling entry for traders betting on the merger's success, the underlying business fundamentals remain severely deteriorated, rendering it unsuitable for any long-term capital preservation strategy.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.467893
AutoARIMA0.467942
MSTL0.468930
AutoTheta0.478777

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 25%
H-stat 8.98
Ljung-Box p 0.000
Jarque-Bera p 0.543
Excess Kurtosis -0.73
Attribute Value
Sector Healthcare
Market Cap 18,585,884
Forward P/E -3.49
Beta -0.23
Website https://www.senseibio.com

Info Dump

Attribute Value
52 Week Change 1.7508855
Address1 1,405 Research Boulevard
Address2 Suite 125
All Time High 530.0
All Time Low 5.0
Ask 17.76
Ask Size 200
Audit Risk 9
Average Daily Volume10 Day 105,202
Average Volume 52,333
Average Volume10Days 105,202
Beta -0.231
Bid 11.49
Bid Size 200
Board Risk 8
Book Value -102.427
City Rockville
Compensation Risk 8
Country United States
Currency USD
Current Price 13.85
Current Ratio 14.393
Date Short Interest 1,780,012,800
Day High 16.52
Day Low 13.755
Ebitda -185,506,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.982
Enterprise Value -182,255,600
Exchange NGM
Exchange Timezone Name UTC
Fifty Day Average 21.492
Fifty Two Week High 36.76
Fifty Two Week Low 6.325
Financial Currency USD
First Trade Date Epoch Utc 1,783,690,200
Float Shares 811,874
Forward Eps -3.9732
Forward P E -3.4858553
Free Cashflow -92,236,624
Full Time Employees 29
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,780,531,200
Gross Margins 0.0
Held Percent Insiders 0.2829
Held Percent Institutions 1.53024
Implied Shares Outstanding 1,341,941
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Last Fiscal Year End 1,767,139,200
Last Split Date 1,750,118,400
Last Split Factor 1:20
Long Business Summary Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Long Name Sensei Biotherapeutics Inc
Market Cap 18,585,884
Max Age 86,400
Message Board Id finmb_732397
Most Recent Quarter 1,774,915,200
Net Income To Common -184,456,992
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 932,159,744
Number Of Analyst Opinions 3
Open 15.21
Operating Cashflow -24,092,000
Operating Margins 0.0
Overall Risk 8
Payout Ratio 0.0
Phone 240 243 8000
Previous Close 0.0
Price Hint 2
Profit Margins 0.0
Quick Ratio 14.291
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Regular Market Day High 16.52
Regular Market Day Low 13.755
Regular Market Open 15.21
Regular Market Previous Close 0.0
Regular Market Volume 219,467
Return On Assets -0.95238
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 1,341,941
Shares Percent Shares Out 0.5949
Shares Short 798,278
Shares Short Previous Month Date 1,777,507,200
Shares Short Prior Month 834,411
Short Name Sensei Biotherapeutics, Inc.
Short Percent Of Float 0.84599996
Short Ratio 23.85
State MD
Symbol SNSE
Target High Price 55.0
Target Low Price 50.0
Target Mean Price 51.66667
Target Median Price 50.0
Time Zone Full Name America/New_York
Time Zone Short Name EDT
Total Cash 202,792,992
Total Cash Per Share 151.119
Total Debt 1,039,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield NaN
Trailing Eps -142.72
Trailing Peg Ratio None
Two Hundred Day Average 16.710743
Underlying Symbol SNSE
Uuid 0e733dd6-5a8f-3a8d-91c0-8d1a525a8226
Volume 219,467
Website https://www.senseibio.com
Zip 20,850